World Investment Advisors Grows Stock Holdings in Sanofi (NASDAQ:SNY)

World Investment Advisors grew its stake in shares of Sanofi (NASDAQ:SNY) by 4.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 50,544 shares of the company’s stock after acquiring an additional 2,114 shares during the period. World Investment Advisors’ holdings in Sanofi were worth $2,438,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in SNY. Raymond James Financial Inc. purchased a new position in Sanofi during the fourth quarter valued at approximately $135,933,000. Boston Partners grew its position in shares of Sanofi by 86.4% during the 4th quarter. Boston Partners now owns 5,396,531 shares of the company’s stock valued at $260,607,000 after purchasing an additional 2,501,073 shares in the last quarter. Magnetar Financial LLC increased its holdings in shares of Sanofi by 104.3% in the fourth quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company’s stock worth $161,103,000 after purchasing an additional 1,705,148 shares during the period. DAVENPORT & Co LLC increased its stake in Sanofi by 40.7% in the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock worth $110,715,000 after acquiring an additional 664,455 shares during the last quarter. Finally, Thrivent Financial for Lutherans raised its stake in Sanofi by 36.0% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,943,761 shares of the company’s stock valued at $93,774,000 after purchasing an additional 514,542 shares in the last quarter. 14.04% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SNY. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. The Goldman Sachs Group assumed coverage on Sanofi in a report on Friday, March 21st. They issued a “neutral” rating and a $65.00 price objective for the company. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $62.50.

Sanofi Stock Down 4.8 %

Shares of NASDAQ:SNY opened at $51.98 on Friday. Sanofi has a 12-month low of $45.22 and a 12-month high of $60.12. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The stock’s 50-day moving average price is $55.37 and its 200-day moving average price is $52.71. The stock has a market capitalization of $131.92 billion, a P/E ratio of 20.88, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, equities analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.